Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02313909 · ClinicalTrials.gov registry record · Phase 3
Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)
A Phase 3 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 7,213
- Enrollment target
NCT02313909: Clinical Trial Phase 3 study, sponsored by Bayer.
NCT02313909 is a Phase 3 study that was terminated before completion, run by Bayer. The registered enrollment target is 7,213 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (834% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02313909, a Phase 3 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 7,213 participants
- Enrollment target
Study Summary
This is a study in patients who recently had a brain attack (stroke) and in whom no clear cause of the stroke could be identified. These strokes are likely due to a blood clot and therefore, can be called embolic stroke of undetermined source. The abbreviation is ESUS. The study will compare 2 blood thinners. Patients will be randomly assigned to either Rivaroxaban 15 mg or Aspirin 100 mg and the study is intended to show, if patients given rivaroxaban have fewer blood clots in the brain (stroke) or in other blood vessels.
Primary Outcome
Components of composite efficacy outcome (adjudicated) includes stroke (ischemic, hemorrhagic, and undefined stroke, TIA with positive neuroimaging) and systemic embolism. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred.
Interventions
- DRUG Rivaroxaban (Xarelto, BAY59-7939)
- DRUG Acetylsalicylic acid (Aspirin, BAY1019036)
- OTHER Rivaroxaban-Placebo
- OTHER Aspirin-Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,213 participants |
| Start Date | 2014-12-23 |
| Est. Completion | 2018-02-15 |
| Phase | Phase 3 |
Why NCT02313909 stopped before completion
NCT02313909 is an interventional study that assigns participants to a tested intervention. Its 7,213 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (834% higher).
The record links to 0 conditions, and to 4 interventions - of which Rivaroxaban (Xarelto, BAY59-7939) is the first listed.
NCT02313909 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02313909 about?
NCT02313909 is a clinical study titled "Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)". This is a study in patients who recently had a brain attack (stroke) and in whom no clear cause of the stroke could be identified. These strokes are likely due to a blood clot and therefore, can be called embolic stroke of undetermined source. The abbreviation is ESUS. The study will compare 2 blood...
What is the current status of trial NCT02313909?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 7,213 participants. The study started on 2014-12-23. Estimated completion is 2018-02-15.
What interventions are being tested in trial NCT02313909?
The interventions under investigation include: Rivaroxaban (Xarelto, BAY59-7939) (DRUG), Acetylsalicylic acid (Aspirin, BAY1019036) (DRUG), Rivaroxaban-Placebo (OTHER), Aspirin-Placebo (OTHER).
Who is sponsoring clinical trial NCT02313909?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02313909's enrollment target sits among peer trials
7,213 34th of 2000 higher than 1,967 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05049837 · 7,200 participants
PROSPECT - Profiling of Resistance Patterns & Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax and Therapeutic Target Identification
- NCT06714929 · 7,200 participants · NA
Advancing Water Security: A Community Participatory School-Based Hydration Intervention
- NCT06843720 · 7,100 participants · NA
Expanding Access to Cervical Cancer Screening Through Primary HR-HPV Testing and Self-sampling: a Multicomponent Intervention for Safety Net Health Systems
- NCT02915198 · 7,410 participants · Phase 4
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI